Key Highlights

● Eloxx Pharmaceuticals priced a $66.0 million public offering and uplisted to Nasdaq in June 2026, advancing exaluren through the Phase 2b EXACT Study in Alport syndrome with topline data expected mid-2027.

● First Tracks Biotherapeutics spun out of AnaptysBio in April 2026 with roughly $180 million in cash and about two years of runway, trading around a $1.34 billion market Capitalization by mid-September 2026.

● Medline Inc. completed the largest US IPO of 2025, raising about $6.26 billion, and posted trailing Revenue near $29.94 billion, but cut full-year adjusted EBITDA guidance and faces a securities investigation.

● AgomAb Therapeutics trades below its $16.00 IPO price, with shares near $13.06 and a net loss near $93 million, as its Phase 2a fibrostenosing Crohn's disease readout for ontunisertib approaches.

A verified, source-anchored look at five very different Nasdaq-listed healthcare stocks, one large-cap medical-supply giant and four clinical-stage drug developers, and the specific catalysts and risks that separate them this autumn.

Five Tickers, Five Completely Different Risk Profiles

The five symbols in this basket are often lumped together as a biotech watchlist, but they are not remotely alike. One of them, Medline, is a roughly $40 billion medical-products company; the other four are pre-revenue drug developers whose fortunes turn on single clinical readouts. Grouping them is only useful if the distinctions stay sharp.

Each company below has been checked against its own filings, press releases and financial data providers, and every figure is attributed. Where the popular micro-cap biotech label is simply wrong, as it is for Medline and, arguably, for First Tracks, that is stated plainly. The goal is a clear-eyed September 2026 map of what each name actually is, what could move it, and what could break it.

A Biotech Tape That Has Rewarded IPOs, For Now

The backdrop matters. According to a market summary, biotech and pharma IPOs averaged roughly 55% returns through mid-2026, against about negative 4.4% for the broader IPO market, while the Nasdaq Biotechnology index gained around 13% year-to-date. The same summary noted the sector raised roughly $5 billion through follow-on stock offerings, described as about triple the prior year, and that three large acquisitions were announced within a month: AbbVie's deal for Apogee Therapeutics, GSK's for Nuvalent and Vertex's for Crinetics Pharmaceuticals, each said to be valued above $10 billion.

Forecast and caution belong together here. That same report described interest rates as still high, a genuine headwind for cash-burning developers whose value sits in distant cash flows. A friendly IPO window can close quickly. So the recent strength is real, but it is not a guarantee that any single name below will follow the average. Four of these five companies have no approved product and no revenue, and their charts can move violently on data that has nothing to do with the index.

Eloxx Pharmaceuticals (NASDAQ:ELOX): A Fresh Nasdaq Uplisting Riding on One Readthrough Bet

Eloxx Pharmaceuticals is a clinical-stage company developing small molecules designed to modulate the ribosome and promote readthrough of premature stop codons, the nonsense mutations behind several rare genetic diseases.

In June 2026 the company priced a $66.0 million public offering, 2,975,000 shares at $11.00 plus 3,025,000 pre-funded warrants at $10.99, and uplisted to Nasdaq, with trading beginning June 9, 2026 and closing expected June 10. Its lead candidate, exaluren (formerly ELX-02), is now in the Phase 2b EXACT Study in nonsense-mutation Alport syndrome; a company profile notes the first two patients were dosed in early September 2026, with topline data expected mid-2027 and final results by year-end 2027.

This is a genuine micro-cap. Market data showed a market capitalization near $64 million in mid-September and a fresh filing for a secondary offering of 600,000 shares dated September 11, 2026, a reminder that ongoing dilution is part of the story. With a single lead program and data more than a year away, this is a high-conviction, high-risk name where the science, not the tape, will decide the outcome.

First Tracks Biotherapeutics (NASDAQ:TRAX): An AnaptysBio Spin-Out With Real Cash

First Tracks Biotherapeutics is the least micro-cap of the four developers here. It was spun out of AnaptysBio through a one-for-one share distribution on April 6, 2026 and began trading on the Nasdaq Global Select Market on April 20, 2026 with roughly $180 million in cash and about two years of runway.

The pipeline is antibody-based and aimed at autoimmune and inflammatory disease. Its lead asset, ANB033, is a CD122 antagonist in Phase 1b for celiac disease and eosinophilic esophagitis; the portfolio also includes rosnilimab, which completed a Phase 2b study in rheumatoid arthritis, and ANB101, a BDCA2 modulator in Phase 1a.

A company profile put the shares near $37.57 after the close on September 14, 2026, with a market cap around $1.34 billion and a 52-week range of roughly $14.72 to $49.91, a wide swing that captures the Volatility of a newly independent developer. Management said after its August 12 results that it expects to treat patients across four indications in 2027. The next scheduled Earnings date is November 12, 2026, and clinical updates through 2027 are the real catalysts. A healthy cash balance buys time, but not certainty.

Vogenx (NASDAQ:VOGX): A Brand-New Metabolic-Disease IPO Trading Well Above Its Offer

Vogenx is the freshest listing on this list. Per market data and a company profile, Vogenx completed its Nasdaq IPO on August 12, 2026, pricing at $13.00 per share and raising roughly $81 million, with JonesTrading involved in the deal. The Raleigh, North Carolina company was founded in 2021, is clinical-stage, and reported a very small headcount.

Its focus is metabolic disorders, specifically post-bariatric hypoglycemia and gastroparesis, with named candidates including mizagliflozin and VGX-2857, plus VGX-001, described as a human monoclonal antibody for type 1 diabetes.

A company profile listed a price near $31.73 as of September 4, 2026, well above the $13 IPO price, a move that reflects enthusiasm rather than fundamentals, since there is no approved product and no revenue. Newly public micro-caps that trade at large premiums to their Offer Price can reprice sharply once lock-ups expire or the first post-IPO data or financing arrives. Watch for the company's first Quarterly Report and clinical timelines as the events that will actually test the valuation.

Medline Inc. (NASDAQ:MDLN): The Odd One Out, a Large-Cap Medical-Products Giant, Not a Biotech

Here the micro-cap biotech framing breaks down entirely, and honesty demands saying so plainly. Medline Inc. is not a drug developer at all. It is a large medical-products and Supply company that completed the largest US IPO of 2025 when it debuted on Nasdaq on December 17, 2025, raising about $6.26 billion in a private-equity-backed listing.

The scale is a different universe from the others. A company overview showed trailing revenue near $29.94 billion, up about 12.1%, and a market capitalization around $42.77 billion in mid-September 2026, with shares near $32.53 and a 52-week range of roughly $31.87 to $50.88, meaning the stock was trading close to its lows.

The recent tape has been rough. That overview cited Q2 results on August 5, 2026 with adjusted EPS of $0.50 beating a $0.32 consensus, but a downward revision to full-year adjusted EBITDA guidance, to $3.4 billion from $3.6 billion, attributed to Inflation and fire-related costs, plus a securities investigation announced by a plaintiffs' firm in late August. Several analysts trimmed targets. This company belongs on a health technology radar as a scaled operator with real Cash Flow and real legal and guidance overhangs, not as a speculative biotech.

AgomAb Therapeutics (NASDAQ:AGMB): A Belgian Fibro-Inflammatory Player Trading Below Its IPO Price

AgomAb Therapeutics NV is a clinical-stage, Antwerp-based biopharmaceutical company focused on fibro-inflammatory disease. Per a company profile, it priced its Nasdaq IPO on February 6, 2026 at $16.00 per share, offering 12.5 million shares.

Its lead candidate is ontunisertib (AGMB-129), an oral, gastrointestinal-restricted ALK5/TGFbetaR1 inhibitor in Phase 2a for fibrostenosing Crohn's disease, with AGMB-447, an inhaled ALK5 inhibitor, in Phase 1 for idiopathic pulmonary fibrosis.

Unlike Vogenx, this company sits below its offer price. The same profile showed shares near $13.06 as of September 11, 2026, a market cap around $643 million, a 52-week range of roughly $8.75 to $17.82, and a net loss near $93 million. A stock trading under its IPO price with a large accumulated loss is priced for skepticism; the Phase 2a Crohn's readout is the pivotal event, and a clean result could re-rate the shares while a miss could pressure them hard. Aggregator-cited analyst targets are optimistic, but they are not company guidance.

What Investors Should Watch

Because these five diverge so sharply, the watch list is really five separate lists. For Eloxx, the dilution cadence and the exaluren EXACT Study timeline into 2027 dominate. For First Tracks, the November 12 earnings date and the plan to enter four indications next year are the markers. For Vogenx, the first post-IPO quarter and any lock-up dynamics will test a price that already sits far above the $13 offer.

Medline is a different exercise: watch the EBITDA guidance path, the fire- and inflation-related cost commentary, and the trajectory of the securities investigation, since those, not clinical data, drive it. For AgomAb, the fibrostenosing Crohn's Phase 2a result is the single most important event, with the below-IPO price signaling how much doubt is already baked in. Across all four developers, cash runway and financing terms remain the quiet variables that can matter more than any headline.

One Scaled Operator, Four Very Different Bets on Unproven Science

All five tickers are real, Nasdaq-listed and verifiable as of mid-September 2026, but the popular shorthand that bundles them as micro-cap biotech is inaccurate. Medline is a large-cap medical-supply operator; First Tracks is a well-capitalized, roughly billion-dollar developer; and only Eloxx truly fits the micro-cap description, with Vogenx and AgomAb as small-cap clinical names. The sector's IPO strength in 2026 is genuine and has rewarded new listings, yet four of these companies have no product, no revenue and binary catalysts ahead.